27 April 2021
: Case report
A Rare Case of Pembrolizumab-Induced Dermatomyositis in a Patient with Cancer of Unknown Primary Origin
Challenging differential diagnosis, Unusual or unexpected effect of treatment, Diagnostic / therapeutic accidents, Unexpected drug reaction, Rare disease
Kensaku Takatsuki1AEF, Toyoshi Yanagihara2ADEF*, Ayaka Egashira2E, Naruhiko Ogo2E, Seiji Yoshizawa1DE, Syunya Sunami3D, Tatsuma Asoh2D, Takashige Maeyama2ADFGDOI: 10.12659/AJCR.930286
Am J Case Rep 2021; 22:e930286
Figure 2. The clinical course of the case. CK – creatine kinase; CRP – C-reactive protein; IVIg – intravenous immunoglobulin; LVFX – levofloxacin; mPSL – methylprednisolone; PSL – prednisolone.